ClinicalTrials.gg
CompletedNCT01730482Updated Dec 18, 2013

A Study to Assess the Absorption, Metabolism and Excretion of Migalastat Hydrochloride (AT1001-014)

A Phase 1 interventional study of [14C] AT1001 in Fabry Disease, sponsored by Amicus Therapeutics. Completed. Open to male participants aged 30 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-12-18.

Sponsored by Amicus Therapeutics (part of BioMarin Pharmaceutical) · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
30 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 26 studies in Fabry Disease by BioMarin Pharmaceutical — 3 open to participants now, 4 under way, 2 of them phase 3. Fabry Disease · BioMarin Pharmaceutical.

Enrollment
17th of 19
6 · median 20
Started
2011
with 6 others
Phase 1
5 of 26
none open now
Registered
13th of 26
by date

Among the 26 studies in Fabry Disease by BioMarin Pharmaceutical, this one is the 17th largest by enrollment of the 19 interventional ones that give a count, is one of 7 that started in 2011, is one of 5 in phase 1, and was the 13th registered.

Fabry Disease

244 studies on the registry are indexed under Fabry Disease; 54 are open to participants now.

Browse Fabry Disease studies →

Open to participants now

3 of the 26 studies in Fabry Disease by BioMarin Pharmaceutical are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 44 Fabry Disease studies recruiting now, 31 (70%) set no upper age limit and 11 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: 30 Years to 55 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Fabry Disease by BioMarin Pharmaceutical, or all of them as a file.
02

Study summary

This study is designed to describe the metabolism of AT1001 (migalastat HCl) and the contribution of metabolism and urinary excretion to its overall elimination as part of the continuing assessment of the safety and effectiveness of the drug.

This is a Phase 1, single-site, open-label, single dose study of the absorption, metabolism and excretion of radiolabeled AT1001 in healthy male subjects between 30 and 55 years of age, inclusive. Six subjects will be dosed, with the goal of having at least 4 subjects complete the study through follow-up. All subjects will be screened within 28 days before admission to the Clinical Unit. Subjects will be confined to the clinical unit for 10 days after dosing and will return to the clinic for a follow-up visit 28 days after dosing.

Each subject will receive a single oral dose of AT1001 as an aqueous solution containing 150 mg [14C] AT1001 (1 μCi). Blood, duodenal bile, expired air, urine, and feces samples will be collected at specified time points after dosing throughout the period of confinement at the study site. Safety will be assessed throughout the study by monitoring clinical laboratory tests, ECGs, physical examinations, vital signs, and adverse events. The total duration of the study for each subject is approximately 8 weeks.

03

Conditions studied

  • Fabry Disease

Browse trials for

Keywords

  • excretion
  • healthy volunteer
  • migalastat hydrochloride
  • AT1001
  • pharmacokinetics
  • Fabry disease
04

Who can participate

Ages eligible
30 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male subjects between the ages of 30 and 55 years, inclusive
  • (BMI) of >=18.0 to \<=30.0 and weighing at least 60 kg
  • Anticipated, regular, average bowel movements of 1-2 per day
  • No abnormal findings on the physical exam, vital signs, serum chemistry, hematology, and urinalysis values, as deemed by the principal investigator
  • Willing to avoid taking of all over-the-counter medications 7 days and all prescription drugs 14 days prior to Day -1
  • Willing to abstain from sexual intercourse or employ a barrier method of during the inpatient clinic confinement and until the follow-up visit
  • Willing to avoid ingestion of broccoli, brussels sprouts, grapefruit, grapefruit juice, or charbroiled meat during the period of confinement in the clinical unit
  • Willingness to consume a fiber-rich diet during the period of confinement in the clinic
  • Willingness to avoid vigorous physical activity during inpatient clinic confinement and through the follow-up visit
  • Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, other study procedures, and study restrictions
  • Provide written to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Any previous or ongoing illness, medical condition, medical history, physical findings, finding, or laboratory abnormality that, in the investigator's opinion, could affect the safety of the subject, or alter the absorption, distribution, metabolism, or excretion of the study drug, or could impair the assessment of study results
  • History or presence of significant ophthalmic, cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic or psychiatric disease
  • History of a major surgical procedure within 30 days before screening
  • History of blood or plasma donation or blood loss (>400 mL) within 60 days before screening
  • History of drug or alcohol abuse or addiction within 2 years before screening
  • Intake of more than 2 alcoholic drinks per day within the past 7 days or use of alcohol-, grapefruit-, or caffeine-containing foods or beverages within 72 hours prior to Day -1
  • Self-reported smoker (occasional or frequent) or positive urine cotinine test (measured at screening and baseline) exceeding the local laboratory's lower limit of detection.
  • Presence or history of severe adverse reaction to any drug; history of or allergic reaction to AT1001 or related iminosugars
  • Receipt of any agent or participation in any other interventional clinical trial within the past 30 days
  • Participation in any clinical study involving administration of [14C] labeled compound(s) within the last 12 months. A subject's previous effective dose will be reviewed by the medical investigator to ensure there is no risk of contamination/carryover into the current study
  • At Day -1, a drug toxicology screen positive for any illicit substances, or alcohol
  • Anticipated need for alcohol, tobacco, or any drug during the period of confinement in the clinical unit
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    [14C] AT1001 Arm

    Each subject will receive a single oral dose of 150 mg of \[14C\] AT1001 as an aqueous solution containing 1 μCi AT1001 on Study Day 1.

    Drug: [14C] AT1001

Interventions

  • DrugLarazotide acetateStudies of Larazotide acetateLarazotide acetate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    150 mg of \[14C\] labelled AT1001 will be administered as a solution (prepared by weighing 150 mg of AT1001 powder and dissolving in 100 mL of water). The entire solution will be swallowed orally. After ingestion of study medication, the dosing bottle will be rinsed with 50 mL of water and this will be ingested by the subject. This rinse procedure should be performed twice. Following the second rinse ingestion, the subjects should be instructed to drink additional water to bring the total volume ingested to 240 mL.

06

What researchers measure

Primary outcomes

  1. Recovery of total radioactivity in urine

    Urine will be collected: pre-dose (-12-0 hours), 0-12 and 12-24 hours on Day 1, 24-hourly on Days 2-10; the last sample will be collected on Day 11. Total radioactivity excreted in urine will be calculated for the entire collection period. The excretion rate will be calculated from total radioactivity collected in urine, divided by the duration of collection. The percentage of dose excreted in urine will be calculated from the total amount excreted in urine divided by the dose administered, multiplied by 100.

    Time frame: Days 1 to 11

  2. Recovery of total radioactivity in feces

    Feces will be collected: predose (-24 to 0 hours); all bowel movements post-dose will be collected on Days 1 to 10; the last sample will be collected on Day 11. Total radioactivity excreted in feces will be calculated for the entire collection period. The excretion rate will be calculated from total radioactivity collected in feces, divided by the duration of collection. The percentage of dose excreted in feces will be calculated from the total amount excreted in feces divided by the dose administered, multiplied by 100.

    Time frame: Days 1 to 11

  3. Presence of radioactivity in expired air

    Expired air will be collected: pre-dose and at 2, 4, 6 and 24 hours after dosing. Each subject will blow into a measured volume of sodium hydroxide solution containing phenolphthalein, until an indicator changes color, showing that the sodium hydroxide is saturated. This sodium hydroxide solution will be analysed for radioactive content. If radioactivity is detected the total amount in expired air during the collection period will be calculated.

    Time frame: Day 1

  4. Plasma AT1001 pharmacokinetic parameters

    Blood samples will be collected: Pre-dose, at 30 minutes, and 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216 and 240 hours after dosing. Non-compartmental pharmacokinetic parameters will be calculated for plasma AT1001: area under the drug concentration-time curve (AUC) from time zero to the time of the last measurable concentration, AUC from time zero to infinity, maximum observed drug concentration, time of the maximum drug concentration, apparent terminal elimination rate constant and apparent elimination half life.

    Time frame: Days 1 to 10

  5. Plasma total radioactivity pharmacokinetic parameters

    Blood samples will be collected: Pre-dose, at 30 minutes, and 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216 and 240 hours after dosing. Non-compartmental pharmacokinetic parameters will be calculated for plasma radioactivity: area under the drug concentration-time curve (AUC) from time zero to the time of the last measurable concentration, AUC from time zero to infinity, maximum observed drug concentration, time of the maximum drug concentration, apparent terminal elimination rate constant and apparent elimination half life.

    Time frame: Days 1 to 10

Secondary outcomes

  1. Number of subjects with adverse events as a measure of safety and tolerability

    Adverse events (AEs) will be collected from the start of Investigation Product and until the follow-up visit.

    Time frame: Day 1 to Day 29

  2. Measure of clinical laboratory test values to access safety and tolerability

    Clinical laboratory tests will include hematology, coagulation tests, clinical chemistry, urinalysis, drug and toxicology screen, Hepatitis A and HIV screen.

    Time frame: Upto 8 weeks

  3. Physical examination to access safety and tolerability

    Physical examination results will be categorized as normal, abnormal clinically significant, or abnormal not clinically significant

    Time frame: Upto 8 weeks

  4. Measure of vital signs to access safety and tolerability

    Vital sign measurements will include pulse, respiratory rate, blood pressure, and oral temperature). Subjects should be in a supine position for at least 5 minutes prior to taking measurements.

    Time frame: Upto 8 weeks

  5. Measure of ECG to access safety and tolerability

    Electrocardiograph (ECG) is a machine that measures the electrical activity of the heart and records changes in the hearts' rhythm. All subjects will undergo ECG testing.

    Time frame: Upto 8 weeks

  6. The blood to plasma ratio of total radioactivity

    The ratio of plasma to blood radioactivity will be calculated at 2, 4, 6 and 24 hours after administration of AT1001.

    Time frame: Day 1

  7. Characterization of metabolites in plasma, urine, duodenal bile and fecal homogenates

    An Entero-Test capsule will be ingested to collect duodenal bile and will be removed after sample collection. Metabolite elucidation and identification will be performed in the collected plasma, urine doudenal bile, and fecal samples, if feasible, under a separate study. Results will be summarized in a separate report.

    Time frame: Day -1 to Day 11

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2011, a primary completion of Sep 2011 and a completion of Sep 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2012
First posted
Nov 21, 2012
Start
Aug 2011
Primary completionActual
Sep 2011
CompletionActual
Sep 2011
Last update
Dec 18, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01730482
Responsible party
Sponsor
First posted
Nov 21, 2012
Start date
Aug 2011
Primary completion
Sep 2011
Completion
Sep 2011
Last update
Dec 18, 2013

Study contacts

Medical Monitor, Clinical Research
study director · Amicus Therapeutics

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Larazotide acetate

Start the discussion